Pharmacoeconomic Evaluation of Magnesium Isoglycyrrhizinate Preventing Liver Damage Induced by Chemo- therapeutic Drugs for Gastric Cancer / 中国药房

OBJECTIVE：To ev aluate pha rmacoeconomics of magnesium isoglycyrrhizinate preventing liver damage induced by chemotherapeutic drugs for gastric cancer ，and to provide reference for rational use of liver-protecting drugs. METHODS ：Totally 200 inpatient medical records were collected from our hospital retrospectively during Jan. 2018-Feb. 2020，and then divided into group A （prophylactic use of magnesium isoglycolate ，50 cases），group B （prophylactic use of magnesium isoglycolate combined with TCM prescriptions ，50 cases），group C （prophylactic use of polyene phosphatidylcholine ，50 cases） and group D （non-prophylactic use of liver-protection drugs ，50 cases）. The effects （total response rate ）of four plans preventing liver damage were evaluated. Pharmacoeconomic evaluation was analyzed by cost-minimization analysis and cost-effectiveness method ， sensitivity analysis was carried out at the same time . RESULTS ：Total response rates of group A ，B，C and D were 94.00％， 96.00％，82.00％ and 72.00％. The total response rates of group A and B had no statistical significance （P＞0.05），but were significantly higher than those of group C and D （P＜0.05）；total response rate of group C was significantly higher than that of group D （P＜0.05）. The costs of groups A ，B，C and D were 1 936.70，2 086.96，1 800.91，2 975.42 yuan. The cost-minimization analysis was used to compare the therapeutic plan of group A and B ，and plan of group A was more economical. The cost-effectiveness method was used to compare therapeutic plan between group C and D ，and the plan of group C was more economical. The cost-effectiveness method was used to compare therapeutic plan between group A and C ，and the cost-effectiveness ratio of 2 groups were 2 060.32 and 2 196.2 3，incremental cost-effectiveness ratio was 1 131.58，and the plan of group A was more economical. Above conclusion were supported by the results of sensitivity analysis. CONCLUSIONS ：The cost-effectiveness of magnesium isoglycyrrhizinate preventing liver damage induced by chemotherapeutic drugs for gastric cancer is better than magnesium isoglycyrrhizinate combined with TCM prescription ， polyene phosphatidylcholine and non-prophylactic use of liver-protecting drugs ，showing economical advantage.

Expression of p53 and Vascular Endothelial Growth Factor in Gastric Cancer; Usefullness as Clinical Significance

PURPOSE: Recent studies have indicated that the p53 tumor suppressor gene and vascular endothelial growth factor (VEGF) play an important role in the angiogenic process of tumors. In this study, the correlation of the expressions of p53 and VEGF and the clinical features in gastric cancer were investigated. METHODS: The expressions of p53 and VEGF in gastric cancer were determined using immunohistochemistry on 98 randomly selected gastric cancer patients that had received curative resection. RESULTS: The expression of p53 and VEGF were observed in 51% and 50% of tumors, respectively. A significant correlation was found between p53 expression and the tumor histological type (P=0.045). The higher the TNM stage, the higher the observed level of p53 expression. The p53 and VEGF expression stati coincided in 70.4% of tumors, with a significant correlation found between the p53 and VEGF stati. Significantly worse survival rates were found in p53-positive and VEGF-positive patients than in those that were p53-negative and VEGF-negative. CONCLUSION: The present results indicated that p53 and VEGF expressions are useful in predicting the prognosis of patients with gastric cancer.

Clinicopathologic Risk Factors of Hepatic Recurrence after Curative Resection for Gastric Cancer

PURPOSE: Recurrence occurs in various forms and in different organs after a curative resection of gastric cancer. The most common location for hematogenous recurrence is the liver. The aim of this study was to evaluate the clinicopathological risk factors associated with hepatic recurrence after surgical treatment of gastric cancer. MATERIALS AND METHODS: We reviewed the medical records of 838 patients who had taken radical surgery for primary gastric cancers at Chonbuk National University Hospital between January 1992 and December 1999. According to the medical records, we retrospectively investigated the association between the clinicopathologic variables and hepatic recurrence. RESULTS: Recurrence of gastric cancer was documented in 201 out of the 838 patients (23.98%). Hepatic recurrences were found in 59 out of 201 patients (29.35%). Multiple logistic regression analysis identified the following as independent risk factors of hepatic recurrence: Lauren's Intestinal type (OR, 6.66; 95% CI, 1.53 to 28.9; p=0.011) and proximal resection of margin below 6 cm (OR, 3.76; 95% CI, 1.03 to 13.67; P=0.045). CONCLUSION: Various studies on clinocopathologic risk factors of liver recurrence with molecular biologic research should make possible the prediction of recurrence and help high-risk patients to find appropriate management.

Clinicopathologic Risk Factors of Hepatic Recurrence after Curative Resection for Gastric Cancer

PURPOSE: Recurrence occurs in various forms and in different organs after a curative resection of gastric cancer. The most common location for hematogenous recurrence is the liver. The aim of this study was to evaluate the clinicopathological risk factors associated with hepatic recurrence after surgical treatment of gastric cancer. MATERIALS AND METHODS: We reviewed the medical records of 838 patients who had taken radical surgery for primary gastric cancers at Chonbuk National University Hospital between January 1992 and December 1999. According to the medical records, we retrospectively investigated the association between the clinicopathologic variables and hepatic recurrence. RESULTS: Recurrence of gastric cancer was documented in 201 out of the 838 patients (23.98%). Hepatic recurrences were found in 59 out of 201 patients (29.35%). Multiple logistic regression analysis identified the following as independent risk factors of hepatic recurrence: Lauren's Intestinal type (OR, 6.66; 95% CI, 1.53 to 28.9; p=0.011) and proximal resection of margin below 6 cm (OR, 3.76; 95% CI, 1.03 to 13.67; P=0.045). CONCLUSION: Various studies on clinocopathologic risk factors of liver recurrence with molecular biologic research should make possible the prediction of recurrence and help high-risk patients to find appropriate management.

Expression of MAGE in Gastric Cancer Tissues

PURPOSE: Among tumor-associated antigens, MAGE (melanoma antigen) was named as cancer/testis specific antigens because they are detected exclusively in the testis or cancer cells, including gastric carcinomas. Due to the elicitation of autoimmunitiy to tumors by these antigens either in vitro or in vivo and their tumor specificity, these antigens, thus, appear to be potential targets for tumor-specific immunotherapy. MATERIALS AND METHODS: The fresh tumor tissue and normal gastric tissue samples were obtained from resected surgical specimens in 53 patients with gastric carcinomas. From the obtained cells, total cellular mRNA was extracted, and RT-PCR and nested PCR were run in 30 and 35 cycles respectively, with two different kinds of primers specially designed to detect six subtypes of MAGE DNA simultaneously. RESULTS: In the 53 normal tissue, there was no expression of MAGE, but in the 53 cancer tissues, MAGE was expressed in 13 tissues (24.5%). Our data did not exhibit any correlation with the expression of the MAGE gene and clinicopathological factors. CONCLUSION: In our data, since 24.5% of gastric cancer tissues expressed MAGE, it should become possible to immunize a significant proportion of patients with advanced gastric carcinomas against the antigens encoded by these genes, provided that more antigenic peptides encoded by the genes of the MAGE family can be identified in the near future.

Total Gastrectomy for Gastric Cancer Involving the Cardia

BACKGROUND: Gastric cardia cancers are relatively rare neoplasms althougth it is reported that their relative incidence among gastric cancers is increasing. At the time of diagnosis, gastric cardia cancers in many cases are already in a more advanced stage in terms of depth of invasion or metastasis to lymph nodes. The purpose of this study was to evaluate the effect of the proximal resection margin on the survival rates for cardia cancer patients who underwent a total gastrectomy without a thoracotomy. METHODS: We retrospectively analyzed 87 patients who had undergone operations for gastric cardia cancers at Eulji College Hospital during the 8 years from Jan. 1988 to Dec. 1995. RESULTS: The most prevalent age group was in the 6th decade (34.5%) and the male-to-female ratio was 2.2:1.0. The TNM classification showed stage I (13.8%), II (10.3%), III (54%) and IV (21.8%). The overall 5-year survival rate was 35.6%, and the survival rates according to the stage were 83.3% in stage I, 87.5% in stage II, 27.1% in stage III, and 0% in stage IV. The 5-year survival rates according to the length of the proximal resection margin (PRM) for all patients were as follows: 22.0% for PRM2 cm (N=52) 44.0% (p=0.0783). The 5-year survival rates according to the length of the PRM for stage III cancers were as follows: 19.7% for PRM2 cm (N=28)(p=0.4090). CONCLUSIONS: These results suggest that the length of the proximal resection margin is not significant as a prognostic factor. We believe a total gastrectomy without a thoracotomy is a reasonable and safe alternative to a thoracotomy approach to the dissection of the mediastinal lymph node in cases of gastric cardia cancer.

The measurement of Serum Soluble IL—2 Receptor in Patients with Malignant Carcinoma of Degestive Systom / 中国免疫学杂志

The serum soluble interleukin 2 receptor(sIL—2R)in 39 patients with malignant tumour of degestive system wasemeasured using by sandwith ELISA with monoclonal and polycional antibodies technigue.The results show the level of sIL—2R was obvious higher than level of sIL—2R of the controls(P